On September 12, 2019 Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (TSX: MDNA,OTCQB: MDNAF), a clinical stage immuno-oncology company, reported that it will present updated clinical results from the Phase 2b clinical trial of MDNA55 for the treatment of recurrent glioblastoma (rGBM) at the Inaugural Targeting Innate Immunity Congress to be held on September 24 and 25, 2019 in Cambridge, MA (Press release, Medicenna Therapeutics, SEP 12, 2019, View Source [SID1234539480]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will discuss recent clinical data on survival outcomes and therapeutic benefit from MDNA55 in rGBM patients, a uniformly fatal type of brain cancer. Medicenna’s lead candidate, MDNA55, simultaneously targets the interleukin-4 receptor (IL-4R), which is over-expressed by tumor cells and its supportive tumor microenvironment (TME) which hides the tumor from the immune system.
The details of the podium presentation are as follows:
Title:
Tipping the balance towards success in a Phase 2b recurrent GBM Trial: Overcoming the
tumor and its microenvironment by targeting the IL4R using MDNA55
Presenter:
Dr. Fahar Merchant, PhD
Date/Time:
Wednesday, September 25, 2019 at 10:00 am
Location:
Hyatt Regency Cambridge, 575 Memorial Drive, Cambridge, MA 02139